Editas Medicine
transitioned in December 2024 from ex-vivo CRISPR-Cas12a (reni-cel, discontinued) to in-vivo gene editing; lead candidate EDIT-401 upregulates LDLR and cut LDL-C, Lp(a) and ApoB by ~90% in non-human primates, IND/CTA targeted for mid-2026.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Genome editing | genome-engineering | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.